Novartis stock

NVS stock price: $90.04 0.59% At close on November 15th, 2019

Updated on:
November 15th, 2019


Novartis appreciated a tiny 0.59% and closed at $90.04.

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers.

Should I buy Novartis stock?

You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. That's why is so important to define your own trading strategy that fits your character as inversor. There are thousands of trading strategies for you to choose, but at we prefer those that are simple but successful.

Currently, Novartis stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean NVS will slide in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is Novartis stock a buy?

Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness. At, we gathered 5 ratings published for NVS stock in the last month.

Is NVS a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-8-29Jefferies Financial Groupn/aBuy
2019-7-5JPMorgan Chase & Co.n/aSell
2019-7-23Kepler Capital MarketsBuyHold
2019-4-10Morgan StanleyEqual WeightUnderweight

Novartis stock analysis

Daily outlook

Novartis ended yesterday at $90.04 and appreciated a tiny 0.59%.

Novartis shares appreciated 0.59% to $90.04 yesterday. Since price and SMA100d lines crossed up on Tuesday, NVS climbed $1.41 (1.59%). On July, NVS hit new all time highs, pushing higher previous ATH of $93.65 recorded on June. New ATHs are usual entry points for many trading setups as there aren't higher resistences.

NVS stock chart (daily)

Weekly outlook

Novartis shares stepped up 1.89% this week, ending at $90.04. With this, it's been 5 green weeks in a row, gaining $3.44 or 4.00%.

Far behind is the all-time high Novartis hit by mid July but price is just -5.22% below that top. Since this week when NVS stock price broke up the SMA20w line, it gained $1.67 (1.89%).

NVS stock chart (weekly)

Novartis stock price history

Novartis IPO was on November 7th, 1996 at $13.47 per share1. Since then, NVS stock surged a 568.40%, with an average of 24.70% per year. If you had invested $1,000 in Novartis stock in 1996, it would worth $5,684.00 today.

1: Adjusted price after possible price splits or reverse-splits.

Novartis stock historical price chart

NVS stock reached all-time highs on July with a price of $95.00.

Novartis stock price target is $105.00

Nobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' NVS stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we only found 1 price prediction for Novartis stock:
NVS stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-7-23ArgusRaises Targetn/a$105.00-
(in average)$0.00$105.000.0%

Financials and fundamental analysis

Earnings date and Earnings per Share

Novartis disappointed experts on January when it published an Earnings per Share (EPS) of $1.24 when the analysts' forecast was $1.33.
NVS earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

In 2018, Novartis annual revenues jumped an excellent 6.05% to $53,166.00 M USD from $50,135.00 marked in 2017. However, its profit margin (compared to revenues) soared to 23.72%, that is $12,611.00 million.

NVS annual Sales and Income evolution
2013$48,290 M-$8,520 M17.6%-
2014$53,634 M11.07%$10,210 M19.0%19.84%
2015$50,387 M-6.05%$17,783 M35.3%74.17%
2016$49,436 M-1.89%$6,712 M13.6%-62.26%
2017$50,135 M1.41%$7,703 M15.4%14.76%
2018$53,166 M6.05%$12,611 M23.7%63.72%

Quarterly financial results

Novartis reported $13,664.00 M in revenues for 2018-Q4, a 4.14% up compared to previous quarter. Reported quarter earnings marked $1,195.00 M with a profit margin of 8.75%. Profit margin depreciated a -3.62% compared to previous quarter when profit margin was 12.37%. When comparing sales to same quarter last year, Novartis sales marked a decent growth and gained a 3.80%.
NVS quarterly Sales and Income evolution
2017-Q2$12,050 M-$1,950 M16.2%-
2017-Q3$11,950 M-0.83%$2,000 M16.7%2.56%
2017-Q4$13,164 M10.16%$1,976 M15.0%-1.20%
2018-Q1$12,929 M-1.79%$2,025 M15.7%2.48%
2018-Q2$13,452 M4.05%$7,768 M57.7%283.60%
2018-Q3$13,121 M-2.46%$1,623 M12.4%-79.11%
2018-Q4$13,664 M4.14%$1,195 M8.7%-26.37%
2019-Q1$11,455 M-16.17%$1,766 M15.4%47.78%

Novartis ownership

When you are planning to invest in a stock, it's always worth to have a look its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Novartis, 0.00% of all outstanding shares are owned by its staff.

In case of Novartis stock, 11.69% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for NVS stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Novartis:

Market cap$206.2 B$151.7 B$95.5 B$109.8 B$354.9 B
Total shares2,290.0 M1,770.0 M1,630.0 M2,490.0 M2,630.0 M
Float shares2,130.0 M1,760.0 M1,630.0 M2,450.0 M2,630.0 M
  - Institutional holdings (%)11.7%76.5%75.0%11.0%69.2%
  - Insider holdings (%)0.0%0.7%0.1%0.0%0.1%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

Novartis summary

Friday, November 15th, 2019
Day range$89.37 - $90.22
Previous close$89.51
Session gain0.59%
Average true range$0.94
50d mov avg$87.17
100d mov avg$88.91
200d mov avg$85.89
Daily pattern
Weekly pattern

Novartis performance

Performance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We compared Novartis against , Bristol-Myers Squibb, GlaxoSmithKline, , Merck, Pfizer, and Teva Pharmaceutical Industries in the following table:
BMYBristol-Myers Squ...25.76%27.23%12.09%
TEVATeva Pharmaceutic...59.13%-12.30%-54.16%

Novartis competitors

One check before trading any stock is to review a list of its competitors, in this case for Novartis. We selected 8 companies as Novartis competitors as they are in the same industry or have similar market objectives.

Latest Novartis stock news